Trial of aripiprazole in the treatment of first-episode schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 64, Issue 1, 2010, Pages 38-43

  Lee, Hwa Young ^a   Ham, Byung Joo ^a   Kang, Rhee Hun ^a   Paik, Jong Woo ^b   Hahn, Sang Woo ^c   Lee, Min Soo ^a  

^a Korea University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Aripiprazole; Efficacy; First episode schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; GLUCOSE; LORAZEPAM; PROLACTIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MONOTHERAPY; NEUROTOXICITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 75649144370     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2009.02039.x     Document Type: Article

References (30)

1. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 1992 149 : 1183 1188.
2. Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. Br. J. Psychiatry Suppl. 1998 172 : 84 89.
3. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002 59 : 921 928.
4. Guttmacher MS. Phenothiazine treatment in acute schizophrenia; effectiveness: The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch. Gen. Psychiatry 1964 10 : 246 261.
5. Huq ZU. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J. Clin. Psychopharmacol. 2004 24 : 220 224.
6. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 1999 25 : 721 729.
7. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J. Clin. Psychiatry 1996 57 (Suppl. 11 68 71.
8. Norman RM, Malla AK. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychol. Med. 2001 31 : 381 400.
9. Taylor DM. Aripiprazole: A review of its pharmacology and clinical use. Int. J. Clin. Pract. 2003 57 : 49 54.
10. Swainston Harrison T, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004 64 : 1715 1736.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association, Washington DC, 1994.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987 13 : 261 276.
13. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987 334 : 1 100.
14. Sheitman BB, Lee H, Strous R, Lieberman JA. The evaluation and treatment of first-episode psychosis. Schizophr. Bull. 1997 23 : 653 661.
15. Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 1999 156 : 544 549.
16. Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M. Aripiprazole: Effectiveness and safety under naturalistic conditions. Exp. Clin. Psychopharmacol. 2007 15 : 569 575.
17. Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr. Scand. 2006 113 : 148 153.
18. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2002 63 : 763 771.
19. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003 60 : 681 690.
20. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2008 3 CD006617.
21. Chan HY, Lin WW, Lin SK et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. J. Clin. Psychiatry 2007 68 : 29 36.
22. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. Int. Clin. Psychopharmacol. 2007 22 : 363 370.
23. Freudenreich O, Holt DJ, Cather C, Goff DC. The evaluation and management of patients with first-episode schizophrenia: A selective, clinical review of diagnosis, treatment, and prognosis. Harv. Rev. Psychiatry 2007 15 : 189 211.
24. Wang PS, Walker AM, Tsuang MT et al. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry 2002 59 : 1147 1154.
25. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am. J. Psychiatry 2003 160 : 1618 1620.
26. Dossenbach M, Hodge A, Anders M et al. Prevalence of sexual dysfunction in patients with schizophrenia: International variation and underestimation. Int. J. Neuropsychopharmacol. 2005 8 : 195 201.
27. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 2004 64 : 2291 2314.
28. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst. Rev. 2006 2 CD004578.
29. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J. Clin. Psychiatry 2001 62 (Suppl. 7 22 31.
30. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004 161 : 1 56.